BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32333990)

  • 21. Intravesical therapy for superficial cancer: need for more options.
    Crawford ED
    J Clin Oncol; 2002 Aug; 20(15):3185-6. PubMed ID: 12149286
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.
    Dalbagni G; Russo P; Sheinfeld J; Mazumdar M; Tong W; Rabbani F; Donat MS; Herr HW; Sogani P; dePalma D; Bajorin D
    J Clin Oncol; 2002 Aug; 20(15):3193-8. PubMed ID: 12149290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors.
    Morales A; Eidinger D; Bruce AW
    J Urol; 2017 Feb; 197(2S):S142-S145. PubMed ID: 28012770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Non-muscle-invasive high-grade bladder cancer].
    Gakis G; Stenzl A; Horn T; Gschwend JE; Otto W; Burger M
    Urologe A; 2015 Apr; 54(4):491-8. PubMed ID: 25802103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial experience of intravesical gemcitabine for patients with high-risk superficial transitional cell carcinoma of the bladder following BCG failure.
    Allchorne P; Lamb BW; Kinsella J; Shamash J; Green JS
    Urol Nurs; 2014; 34(2):95-9. PubMed ID: 24919248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravesical gemcitabine for non-muscle invasive bladder cancer.
    Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
    Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes.
    Gan C; Amery S; Chatterton K; Khan MS; Thomas K; O'Brien T
    J Urol; 2016 Jun; 195(6):1697-703. PubMed ID: 26845426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Adjuvant Intravesical Bacillus Calmette-Guérin Treatment on Patients with High-Grade T1 Bladder Cancer.
    Novotny V; Froehner M; Ollig J; Koch R; Zastrow S; Wirth MP
    Urol Int; 2016; 96(2):136-41. PubMed ID: 26789626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy?
    Golabek T; Palou J; Rodríguez O; Gaya JM; Breda A; Villavicencio H
    World J Urol; 2017 Feb; 35(2):237-243. PubMed ID: 27277599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are cystoscopy and urinary cytology sufficient to identify candidates for subsequent biopsy after bacillus Calmette-Guérin treatment in patients with bladder carcinoma in situ?
    Haase RN; Harving N
    Scand J Urol; 2015; 49(4):338-40. PubMed ID: 25660358
    [No Abstract]   [Full Text] [Related]  

  • 32. Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.
    Dinney CP; Fisher MB; Navai N; O'Donnell MA; Cutler D; Abraham A; Young S; Hutchins B; Caceres M; Kishnani N; Sode G; Cullen C; Zhang G; Grossman HB; Kamat AM; Gonzales M; Kincaid M; Ainslie N; Maneval DC; Wszolek MF; Benedict WF
    J Urol; 2013 Sep; 190(3):850-6. PubMed ID: 23507396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guérin therapy.
    Bassi P; De Marco V; Tavolini IM; Longo F; Pinto F; Zucchetti M; Crucitta E; Marini L; Dal Moro F
    Urol Int; 2005; 75(4):309-13. PubMed ID: 16327296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Side Effects and Tolerability Between Intravesical Bacillus Calmette-Guerin, Reduced-Dose BCG and Gemcitabine for Non-Muscle Invasive Bladder Cancer.
    Kuperus JM; Busman RD; Kuipers SK; Broekhuizen HT; Noyes SL; Brede CM; Tobert CM; Lane BR
    Urology; 2021 Oct; 156():191-198. PubMed ID: 34217763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Controversies in the management of T1 urothelial bladder cancer.
    Azzouz H; Cauberg EC; De Reijke TM
    Minerva Urol Nefrol; 2011 Dec; 63(4):309-15. PubMed ID: 21996986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Squamous cell carcinoma of the urinary bladder after intravesical bacillus Calmette-Guerin therapy for carcinoma in situ: a case report].
    Uemura M; Nishimura K; Nakagawa M; Kanno N; Miyoshi S; Kawano K; Inoue H
    Hinyokika Kiyo; 2004 Nov; 50(11):809-11. PubMed ID: 15628544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.